Join us at booth #2 at the upcoming 12th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12) in Toronto, Canada, June 19-23, 2022, to learn more about our complement serum products and how we can help with your vaccine development projects. ISPPD is the premier meeting for pneumococcal researchers globally. Learn More

Form

ADHC Product Information Sheet

We have developed a method to remove the lgG and lgM antibodies that cause unwanted intrinsic killing while maintaining sufficient complement potency. Beginning with small lots of a few hundred milliliters, we found that the product worked in a variety of applications and we successfully scaled our process to 1 L+ lots in late 2018. Now our antibody-depleted human comple­ment is available for use in vaccine efficacy programs in volumes sufficient to support clinical trials for many years.

This commercial source of human complement has enabled vaccine developers worldwide to reallocate their time and resources previously spent on making small quantities of human complement to new vaccine discoveries.

Register to Download

Register To Watch Webinar
Areas of Interest